Glooko and Danish digital therapeutics company Hedia have launched their combined diabetes care technology provision in the UK to enhance support for diabetic patients who require bolus insulin dosing support in their daily management.
Glooko’s platform enables patients to share diabetes data, including blood glucose readings, insulin doses, and blood pressure with their healthcare providers.
First announced in April 2023, the integration with Hedia Diabetes Assistant allows patients using Glooko’s platform to gain personalised support in calculating insulin doses, which Glooko stated would simplify their diabetes management and support more consistent blood glucose levels.
Glooko CEO Mike Alvarez said: “We are very pleased to bring this algorithm-driven, personalised innovation to diabetes patients and their healthcare teams through our partnership with Hedia.
“With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI [multiple daily injection] therapy.”
Now available in the UK, the companies plan to roll out their offering in other European countries at a later date.
Hedia CEO Lars Christian Lund said: “This joint offering is perfectly aligned with Hedia’s vision to improve the quality of life for people with diabetes and make the best diabetes management tools available.
“In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance, and we recently got Medical Device Regulation (MDR)-certified in Europe. Hedia’s Class IIb medical device designation ensures that patients and their care teams are getting the best solutions.”
Last October, Glooko completed a $100m Series F funding round, which it plans to use for the expansion of its platform into the Middle East and Asia.
In 2023, the California-based company entered a global collaboration with Sanofi to integrate the SoloSmart device, a single add-on connected device developed for use with Sanofi’s SoloStar and DoubleStar insulin injection pens, into its platform with the aim to enhance support for healthcare professionals and individuals with diabetes.
